# Celestia S. Higano

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/celestia-s-higano/

## Facts

| Field | Value |
| --- | --- |
| Citations | 55,562 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 92 |
| i10-index | 287 |
| Last Known Institution | University of British Columbia |
| OpenAlex ID | https://openalex.org/A5001591556 |
| ORCID iD | https://orcid.org/0000-0001-5308-8972 |
| Works | 692 |

## Researcher papers

- [Enzalutamide in Metastatic Prostate Cancer before Chemotherapy](https://scholariq.org/papers/enzalutamide-in-metastatic-prostate-cancer-before-chemotherapy/)
- [Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy](https://scholariq.org/papers/abiraterone-in-metastatic-prostate-cancer-without-previous-chemotherapy/)
- [Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group](https://scholariq.org/papers/design-and-end-points-of-clinical-trials-for-patients-with-progressive-prostate/)
- [Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3](https://scholariq.org/papers/trial-design-and-objectives-for-castration-resistant-prostate-cancer-updated/)
- [Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/prostate-cancer-version-2-2019-nccn-clinical-practice-guidelines-in-oncology/)
- [Prostate Cancer, Version 1.2016](https://scholariq.org/papers/prostate-cancer-version-1-2016/)
- [Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-the-report-of-the-advanced/)
- [Intermittent versus Continuous Androgen Deprivation in Prostate Cancer](https://scholariq.org/papers/intermittent-versus-continuous-androgen-deprivation-in-prostate-cancer/)
- [Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/addition-of-radium-223-to-abiraterone-acetate-and-prednisone-or-prednisolone-in/)
- [Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-report-of-the-advanced/)
- [Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/circulating-tumor-cell-counts-are-prognostic-of-overall-survival-in-swog-s0421-a/)
- [Prostate Cancer, Version 2.2014](https://scholariq.org/papers/prostate-cancer-version-2-2014/)

## Researcher topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Bone health and treatments](https://scholariq.org/topics/bone-health-and-treatments/)

## Researcher university

- [University of British Columbia](https://scholariq.org/institutions/university-of-british-columbia/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.